PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML

NCT06409936 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

160

Enrollment

OTHER

Sponsor class

Conditions

CML, Chronic Phase
Chronic Myeloid Leukemia, Chronic Phase
Chronic Myeloid Leukemia, BCR/ABL-Positive
Chronic Myeloid Leukemia

Interventions

DRUG: Asciminib
DRUG: Nilotinib

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto

Collaborators

[object Object]